

Index

A

- Abatacept, immunosuppression therapy, 270, 293
- Activating transcription factor-4 (ATF4)
 endoplasmic reticulum stress role, 52
 unfolded protein response apoptotic switch, 61
- Activating transcription factor-6 (ATF6)
 endoplasmic reticulum stress sensing, 52, 57
 unfolded protein response apoptotic switch, 61
- Age of onset, T1D, 2
- Altered peptide ligands (APLs), antigen-specific therapy, 251–252
- Anakinra, anti-inflammatory therapy, 271–272, 291
- Anti-inflammatory therapy
 interleukin-1 antagonists
 anakinra, 271–272
 canakinumab, 272
 islet engraftment promotion, 291
 prospects, 277–278
 tumor necrosis factor- α blockade, 271
- Antigen-specific therapy
 clinical trials, 245–246
 dendritic cell engineering, 254–255
 DNA vaccine
 codelivery of antigen and immunomodulatory molecules, 253–254
 glutamic acid decarboxylase, 253
 heat shock protein-60, 253
 insulin, 252–253
 ethylene carbodiimide–fixed splenocyte, 255
 major histocompatibility complex–based therapy
 coated nanoparticles, 254
 dimers, 254
 mechanism of action, 247
 preclinical studies, 243–244
 prospects for study, 255–256
 protein/peptide immunotherapy
 altered peptide ligands, 251–252
 dendritic cell–targeted peptide therapy, 251
 glutamic acid decarboxylase, 242, 248, 277
 heat shock protein-60, 250–262, 277
 insulin, 248–250, 276–277
- Antilymphocyte globulin (ATG), tolerance induction, 29, 272–273
- APLs. *See* Altered peptide ligands
- Apoptosis
 endoplasmic reticulum stress induction
 cell fate, 53
 unfolded protein response components and therapeutic targeting, 59–63
 inhibition for islet engraftment promotion, 291–292
- APSI. *See* Autoimmune polyendocrine syndrome I
- ATF4. *See* Activating transcription factor-4
- ATF6. *See* Activating transcription factor-6
- ATG. *See* Antithymocyte globulin
- Autoantibodies
 antigens. *See* Autoantigens
 assay standardization and harmonization, 86, 88–89, 105
 clinical relevance
 autoimmune disease interrelationships, 96
 children, 93–95
 diagnostic and predictive value in T1D, 9–11
 immunoglobulin G isotype, 97
 Latent Autoimmune Diabetes of Adults, 96
 specificity and T-cell response, 97
 glutamic acid decarboxylase, 91
 human leukocyte antigen allele correlations, 92–93
 humoral autoimmunity in non- β -cell tissues, 98–99
 IA-2, 91
 immune therapy response, 105–106
 insulin, 89–90
 pathogenesis role in T1D, 97–98
 prospects for study, 99
 ZnT8, 91–92
- Autoantigens. *See also specific antigens*
 biomarker utilization, 162, 164
 discovery based on autoantibody epitopes, 89
 identification approaches, 155–156
 immune therapy trial utilization, 162
 polymorphisms, 161–162
 posttranslational modification in production, 149–150
 tolerance loss. *See* Tolerance
 types, localization, and immune response, 87–88, 104–105, 163
- Autoimmune polyendocrine syndrome I (APSI), gene mutations, 86
- Autoimmunity. *See also* Tolerance
 autoantigens. *See* Autoantibodies
 human leukocyte antigen role. *See* Human leukocyte antigen
 mechanisms in T1D, 8–9
 T-cell autoreactivity. *See* T cell

Index

B

- Bacterial infection, T1D risks, 183–184
- B cell. *See also* Autoantibodies
 - adaptive immunity in insulin resistance, 218
- BCG, vaccination and atopy induction, 173
- Bcl-2, unfolded protein response apoptotic switch, 62
- Belatacept, immunosuppression therapy, 293
- β cell
 - embryonic stem cell differentiation
 - culture protocols
 - limitations, 42–43
 - modifications, 43–44
 - history of study, 40–41
 - organogenesis in culture lessons from embryology, 41–42
 - stem cell identification and isolation, 39–40
 - endoplasmic reticulum. *See* Endoplasmic reticulum stress
 - induced pluripotent stem cell differentiation, 44–45
 - insulin resistance and loss, 211–213
 - markers of destruction
 - autoantibodies, 104–106
 - autoreactive T cells, 106–108
 - imaging, 110–112
 - metabolic markers, 108–110
 - pancreas stem cells and fate plasticity, 45–46
 - proliferation studies in immunodeficient mice, 234
 - secretory granule autoantigen production, 128
- Bioluminescence imaging, islet imaging, 112
- Bone marrow transplantation, tolerance induction, 274–275
- Breastfeeding, T1D studies, 13, 184–186
- B- and T-lymphocyte attenuator (BTLA), pathogenic T-cell control, 23
- BTLA. *See* B- and T-lymphocyte attenuator

C

- C4, susceptibility gene studies, 78
- Canakinumab, anti-inflammatory therapy, 272
- CD3
 - antibodies for tolerance induction, 273–274
 - tolerance therapeutic targeting, 29
- CD25
 - islet engraftment promotion with antibodies, 292
 - regulatory T-cell control, 24–25
 - susceptibility gene in T1D, 8
- Celiac disease, genetic and environmental factors, 186
- Cereal, T1D studies, 185–187
- ChgA. *See* Chromogranin A
- CHOP, unfolded protein response apoptotic switch, 62
- Chromogranin A (ChgA)
 - autoantibodies, 96
 - autoantigen activity, 126

- class II antigen presentation, 147–149
- functional overview, 126
- Cod liver oil, T1D prevention, 185
- Cow's milk, risks of T1D development, 13, 184–186
- Coxsackie virus, infection and T1D risks, 182–183, 202, 204
- C-peptide, β -cell function assay, 109
- CSA. *See* Cyclosporin A
- CTLA-4. *See* Cytotoxic T lymphocyte associated-4
- Cyclosporin A (CSA), immunosuppression therapy, 268–269
- Cytotoxic T lymphocyte associated-4 (CTLA-4)
 - abatacept for immunosuppression therapy, 270, 293
 - pathogenic T-cell control, 22–23
 - susceptibility gene in T1D, 8
 - tolerance therapeutic targeting, 31

D

- DC. *See* Dendritic cell
- DEC-205, antigen-specific therapy, 251
- Dendritic cell (DC)
 - antigen presentation. *See* Human leukocyte antigen
 - antigen-specific therapy, 251, 254–255
- DNA vaccine. *See* Antigen-specific therapy

E

- ECDI-SP. *See* Ethylene carbodiimide-fixed splenocyte
- eIF2 α , phosphorylation in endoplasmic reticulum stress, 55–56
- ELISPOT. *See* Enzyme-linked immunospot assay
- Embryonic stem (ES) cell
 - β -cell differentiation
 - culture protocols
 - limitations, 42–43
 - modifications, 43–44
 - history of study, 40–41
 - organogenesis in culture lessons from embryology, 41–42
 - identification and isolation, 39–40
- Endoplasmic reticulum stress
 - apoptosis induction
 - cell fate, 53
 - unfolded protein response components and therapeutic targeting, 59–63
 - autoantigenicity contribution, 126–127
 - diabetes role
 - gestational diabetes, 59
 - T1D, 57–58
 - T2D, 57–59
 - unfolded protein response mutations in rare diabetic syndromes, 54–57
- overview, 51–53
- secretory granule autoantigen production in β cells, 128

- sensors, 52
 - Enterovirus (EV), infection and T1D risks, 181–183, 189, 196–197
 - Enzyme-linked immunospot assay (ELISPOT), autoreactive T-cell identification, 107
 - Eosinophil, interleukin-4 production in adipose tissue, 221
 - Epidemiology, T1D, 2–4
 - ES cell. *See* Embryonic stem cell
 - Etanercept, clinical trials, 271
 - Ethylene carbodiimide-fixed splenocyte (ECDI-SP), antigen-specific therapy, 255
 - EV. *See* Enterovirus
 - Exenatide, islet engraftment promotion, 292
- F**
- Fertile field hypothesis, virus infection, 201
 - FoxP3, regulatory T-cell control, 24–25
- G**
- GAD. *See* Glutamic acid decarboxylase
 - GCN2, endoplasmic reticulum stress function, 55–56
 - Genome-wide association study (GWAS), T1D susceptibility studies, 79–80
 - Geographic distribution
 - T1D, 3–4, 170, 172
 - tuberculosis, 170–171
 - GLP-1. *See* Glucagon-like peptide-1
 - Glucagon-like peptide-1 (GLP-1), islet engraftment promotion, 292
 - Glutamic acid decarboxylase (GAD)
 - antigen-specific therapy
 - DNA vaccine, 253
 - peptide immunotherapy, 242, 248, 277
 - autoantibodies, 91
 - functional overview, 121
 - isoforms, 121–122
 - knockout mice, 122
 - synthesis and processing, 122
 - viral molecular mimicry, 199
 - Gluten, T1D studies, 186–187
 - Glycemic index, T1D risk studies, 188
 - Growth rate, T1D risk studies, 188
 - GWAS. *See* Genome-wide association study
- H**
- Heat shock protein-60 (HSP60), antigen-specific therapy
 - DNA vaccine, 253
 - peptide immunotherapy, 250–252, 277
 - Helminthiasis, treatment and atopy induction, 173
 - Hemoglobin A1c, β -cell function, 110
 - HLA. *See* Human leukocyte antigen
 - HSP60. *See* Heat shock protein-60
- I**
- Human leukocyte antigen (HLA)
 - allele distribution, 72
 - antigen-specific therapy
 - coated nanoparticles, 254
 - dimers, 254
 - autoreactive T-cell identification with tetramer staining
 - class I, 107–108
 - class II, 107
 - class I antigens, 72–73
 - class II antigens
 - antigen presentation to CD4⁺ T cells
 - conventional presentation, 139–142
 - unconventional peptide processing and presentation, 143–149
 - autoimmune disease association, 142–144
 - overview, 71–72
 - functional overview, 72–73
 - genotyping, 74–75
 - nomenclature, 73–74
 - structure, 70–71
 - susceptibility alleles in T1D
 - autoantibody correlations, 92–93
 - class I antigens, 77–78
 - class II antigens
 - DP, 77
 - DR-DQ, 76–77
 - non-HLA susceptibility loci in HLA region, 7–8, 78–79
 - overview, 7, 12, 69, 75–76, 180
 - prospects for study, 80–81
 - Hygiene hypothesis
 - animal model studies of autoimmune disease, 172–173
 - geographic distribution of diseases, 170–172
 - infection epidemiology and autoimmune disease control, 172
 - mechanisms of infection protection effects
 - immune response effects on lymphocytes, 175
 - infectious agents and protective constituents, 174
 - miscellaneous mechanisms, 176
 - Toll-like receptors, 175–176
 - overview in autoimmune disease, 11, 169–170
 - prospects for study, 176
 - therapeutic trial studies, 173
 - viral causation in confounding with T1D, 204
- I**
- IA-2 (ICA512)
 - antigen presentation, 125
 - autoantibodies, 91
 - knockout mice, 124
 - structure, 124
 - IBMR. *See* Instant blood-mediated inflammatory reaction

Index

- ICA512. *See* IA-2
- ICA69. *See* Islet cell autoantigen-69
- IGRP, autoantigen activity, 126
- IL-1. *See* Interleukin-1
- IL-2. *See* Interleukin-2
- IL-4. *See* Interleukin-4
- Immunoblot, autoreactive T-cell identification, 106
- Immunodeficient mice. *See* Nonobese diabetic mouse; Severe combined immunodeficiency mouse
- Immunosuppression therapy
- abatacept, 270
 - cyclosporin A, 268–269
 - islet engraftment promotion, 292–293
 - mycophenolate mofetil, 269
 - overview, 266–268
 - prospects, 277–278
 - rituximab, 269–270
 - vitamin D, 270–271
- Incidence trend, T1D, 4, 265
- Induced pluripotent stem cell (iPSC), β cell
- differentiation, 44–45, 235
- Inflammasome, activation in obesity, 217
- Inositol-requiring enzyme-1 (IRE-1)
- endoplasmic reticulum stress sensing, 52
 - unfolded protein response apoptotic switch, 59–61, 63
- Instant blood-mediated inflammatory reaction (IBMR), islet transplantation, 287, 289, 291
- Insulin
- antigen-specific therapy
 - DNA vaccine, 252–253
 - peptide immunotherapy, 248–250, 276–277
- autoantibodies, 89–90
- B-chain sequence, 120–121
- class II antigen presentation, 145–147
- cow's milk and T1D risks, 186–187
- demethylated DNA release in β -cell
- destruction, 112
- dimerization, 121
- knockout mice, 121
- promoter variants, 118–119, 161
- response and β -cell function, 108–109
- synthesis and processing, 119, 127
- Insulin resistance
- adaptive immunity, 218
 - β -cell loss, 211–213
 - glucose homeostasis, 210–211
 - inflammation, 213–215
 - macrophages in obesity, 215
- Interleukin-1 (IL-1)
- antagonists
 - anakinra, 271–272
 - canakinumab, 272
- islet engraftment and inhibition, 291
- Interleukin-2 (IL-2), regulatory T-cell control, 24–25
- Interleukin-2 receptor common γ -chain. *See* Severe combined immunodeficiency mouse; Nonobese diabetic mouse
- Interleukin-4 (IL-4), eosinophil production in adipose tissue, 221
- iPSC. *See* Induced pluripotent stem cell
- IRE-1. *See* Inositol-requiring enzyme-1
- Islet amyloid protein (IAPP), endoplasmic reticulum stress and diabetes, 59
- Islet cell autoantigen-69 (ICA69)
- gene, 125
 - polymorphisms, 125
- Islet transplantation
- clinical trials, 293
 - donor access and selection, 286
 - encapsulation devices, 289
 - historical perspective, 283–285
 - isolation of islets, 286–287
 - posttransplant treatment
 - complications, 289
 - engraftment enhancement
 - anti-inflammatory therapy, 291
 - apoptosis inhibition, 291–292
 - growth stimulation, 292
 - immunosuppression therapy, 292–293
- immune monitoring and autoimmunity control, 293–294
- prospects, 294–295
- purification of islets, 287
- reimbursement, 289–290
- single-donor transplantation, 285–286
- sites
- alternative sites, 288–289
 - portal site, 287–288
- J**
- JNK. *See* Jun amino-terminal kinase
- Jun amino-terminal kinase (JNK), unfolded protein response apoptotic switch, 62
- L**
- LADA. *See* Latent Autoimmune Diabetes of Adults
- Latent Autoimmune Diabetes of Adults (LADA), 1–2, 10, 96, 122, 210
- M**
- Macrophage, obesity studies
- abundance of cells, 214–215
 - activation
 - alternative activation and insulin sensitivity, 218–221
- overview, 215
- triggers, 216–217

inflammasome activation, 217
recruitment, 217–218
Magnetic resonance imaging (MRI), islet imaging,
111–112
Major histocompatibility complex. *See* Human
leukocyte antigen
MBP. *See* Myelin basic protein
MIC-A, susceptibility gene studies, 78–75
Mixed-meal tolerance test (MMTT), β -cell function,
109
MMF. *See* Mycophenolate mofetil
MMTT. *See* Mixed-meal tolerance test
Mouse models. *See* Nonobese diabetic mouse; Severe
combined immunodeficiency mouse;
Virus infection
MRI. *See* Magnetic resonance imaging
MS. *See* Multiple sclerosis
Multiple sclerosis (MS), class II antigen presentation,
142–145
Mumps, infection and T1D risks, 196
Mycophenolate mofetil (MMF)
immunosuppression therapy, 269
islet engraftment promotion, 292
MyD88, gut microflora regulation, 27
Myelin basic protein (MBP), class II antigen presen-
tation in multiple sclerosis, 143–145

N

Natural history, T1D, 4–14, 180–181
NOD mouse. *See* Nonobese diabetic mouse
Nonobese diabetic (NOD) mouse
 β -cell proliferation studies, 234
human comparison
immune system, 228–229
islets, 228
interleukin-2 receptor common γ -chain knockout,
229–230
NOD-Scid Il-2r γ ^{null} Tg(Ins-rtTA) Tg(TET-DTA)
strain, 233
NOD-Scid Il-2r γ ^{null} Tg(RIP-HuDTR) strain,
233–234
Rag1^{null} Il-2r γ ^{null} Ins2^{Akita} model, 233
Rag1^{null} Prf1^{null} Ins2^{Akita} model, 232–233
NSG mouse. *See* Severe combined immunodeficiency
mouse

O

Obesity. *See* Macrophage
OKT3, islet engraftment promotion, 292
Old friends hypothesis, overview, 11–12

P

PAD. *See* Peptidylarginine deimidase
Pathogenesis, T1D models, 4–6

PD-1. *See* Programmed death-1
Peptidylarginine deimidase (PAD), autoantigen
formation role, 149–150
PERK. *See* Protein kinase RNA-like endoplasmic
reticulum kinase
Peroxisome proliferator activated receptor (PPAR),
macrophage activation regulation,
219–220
PET. *See* Positron emission tomography
Positron emission tomography (PET), islet
imaging, 111
PPAR. *See* Peroxisome proliferator activated receptor
Probiotics, atopy prevention, 173
Programmed death-1 (PD-1), pathogenic T-cell control,
22–23
Protein kinase RNA-like endoplasmic reticulum kinase
(PERK)
eIF2 α phosphorylation, 56
endoplasmic reticulum stress sensing, 52
knockout mouse, 54–56
unfolded protein response apoptotic
switch, 61–63
PTPN22, susceptibility gene in T1D, 8, 79,
188–189

Q

Q-fever, vaccination and atopy induction, 173

R

Rituximab
autoantibody response, 105–106
immunosuppression therapy, 269–270
Rotavirus, infection and T1D risks, 183, 196
Rubella, infection and T1D risks, 196

S

SCID mouse. *See* Severe combined immunodeficiency
mouse
Seasonality, T1D onset, 3
Severe combined immunodeficiency
(SCID) mouse
 β -cell proliferation studies, 234
Hu-PBL-SCID model, 234
Hu-SRC-SCID model, 234–235
human comparison
immune system, 228–229
islets, 228
human immune system engraftment,
229–230
interleukin-2 receptor common γ -chain knockout,
229–230
NOD-Scid Il-2r γ ^{null} Tg(Ins-rtTA) Tg(TET-DTA)
strain, 233

Index

- Severe combined immunodeficiency (SCID) mouse
(*Continued*)
NOD-Scid Il-2r γ ^{null} Tg(RIP-HuDTR) strain,
233–234
NSG mouse
monogenetic models of T1D, 232
normoglycemic mouse, 231
overview, 230–231
streptozotocin-induced diabetes studies, 231
- Single-photon emission computed tomography
(SPECT), islet imaging, 111
- SPECR. *See* Single-photon emission computed
tomography
- Splenocyte. *See* Ethylene carbodiimide-fixed
splenocyte
- Stem cell therapy
 β differentiation. *See* β cell
concerns, 46–47
pancreas stem cells and fate plasticity, 45–46
prospects, 47
T1D as good model, 40
- Streptococcus pneumoniae*, vaccination and atopy
induction, 173
- T**
- T cell
adaptive immunity in insulin resistance, 218
autoantibody specificity and T-cell response, 97
autoreactive T-cell identification
enzyme-linked immunospot assay, 107
immunoblot, 106
major histocompatibility complex tetramer
staining
class I, 107–108
class II, 107
proliferation assay, 106–107
bystander activation in virus infection,
200–201
class II antigen presentation to CD4⁺ T cells
conventional presentation, 139–142
unconventional peptide processing and
presentation, 143–149
immune response regulation in hygiene hypothesis,
175
pathogenic T cells in tolerance dysfunction
activation and function, 20–22
extrinsic control, 23–26
intrinsic control, 22–23
tolerance loss mechanisms with T1D autoantigens
CD4 T cell targets, 158–159
CD8 T cell targets, 159–160
prospects for study, 164–165
- Tacrolimus, islet engraftment promotion, 292
- TG-2. *See* Tissue transglutaminase-2
- Threshold hypothesis, overview, 12
- Tim-3, pathogenic T-cell control, 23
- Tissue transglutaminase-2 (TG-2), autoantigen
formation role, 149
- TLRs. *See* Toll-like receptors
- TNF- α . *See* Tumor necrosis factor- α
- Tolerance
induction therapy
antigen-specific therapy. *See* antigen-specific
therapy
antilymphocyte globulin, 272–273
bone marrow transplantation, 274–275
CD3 antibodies, 273–274
overview, 266, 268, 272
loss mechanisms with T1D autoantigens
autoantigen polymorphisms, 161–162
CD4 T-cell targets, 158–159
CD8 T-cell targets, 159–160
islet epitopes and thymic selection,
160–161
overview, 156–158
prospects for study, 164–165
protein modifications, 161
microRNA regulation, 27–29
pathogen exposure and gut microflora, 26–27
pathogenic T cells
activation and function, 20–22
extrinsic control, 23–26
intrinsic control, 22–23
therapeutic targeting, 29–31
- Toll-like receptors (TLRs), hygiene hypothesis studies,
175–176
- Tumor necrosis factor- α (TNF- α)
blockade, 271, 291
susceptibility gene studies, 78
- Twin studies, T1D, 5
- U**
- Unfolded protein response. *See* Endoplasmic
reticulum stress
- V**
- Virus infection, T1D risks
animal models
bystander activation, 200–201
fertile field hypothesis, 201
islet-specific infection, 199–200
molecular mimicry, 199–200
mouse, 197–199
rat, 198–199
Coxsackie virus, 182–183, 202, 204
direct evidence, 202–203
enterovirus, 181–183, 189, 196–197
hygiene hypothesis confounding, 204
immunization strategies, 204

mumps, 196
pancreas infection evidence in humans
prospects for study, 204
rotavirus, 183, 196
rubella, 196
temporal divergence of viral insult and
 clinical onset, 203
viral signature, 201–202
virus-specific responses, 203–204
Vitamin D
 deficiency and T1D risks, 13–14, 187–188
 immunosuppression therapy, 270–271

W

WFS1, knockout mouse, 56
Wolfram syndrome, diabetes, 56

Z

ZnT8
 autoantibodies, 91–92
 functional overview, 122–123
 knockout mice, 124
 polymorphisms, 161–162